5 research outputs found
Theoretical Investigation of the Methanol Decomposition by Fe<sup>+</sup> and Fe(C<sub>2</sub>H<sub>4</sub>)<sup>+</sup>: A π‑Type Ligand Effect
Density
functional theory has been used to probe the mechanism of gas-phase
methanol decomposition by bare Fe<sup>+</sup> and ligated FeÂ(C<sub>2</sub>H<sub>4</sub>)<sup>+</sup> in both quartet and sextet states.
For the Fe<sup>+</sup>/methanol system, Fe<sup>+</sup> could directly
attach to the O and methyl-H atoms of methanol, respectively, forming
two encounter isomers. The methanol reaction with Fe<sup>+</sup> prefers
initial C–O bond activation to yield methyl with slight endothermicity,
whereas CH<sub>4</sub> elimination is hindered by the strong endothermicity
and high-energy barrier of hydroxyl-H shift. For the FeÂ(C<sub>2</sub>H<sub>4</sub>)<sup>+</sup>/methanol system, the major product of
H<sub>2</sub>O is formed through six elementary steps: encounter complexation,
C–O bond activation, C–C coupling, β-H shift,
hydride H shift, and nonreactive dissociation. Both ligand exchange
and initial C–O bond activation mechanisms could account for
ethylene elimination with the ion products FeÂ(CH<sub>3</sub>OH)<sup>+</sup> and (CH<sub>3</sub>)ÂFeÂ(OH)<sup>+</sup>, respectively. With
the assistance of a π-type C<sub>2</sub>H<sub>4</sub> ligand,
the metal center in the FeÂ(C<sub>2</sub>H<sub>4</sub>)<sup>+</sup>/CH<sub>3</sub>OH system avoids formation of unfavorable multi-σ-type
bonding and thus greatly enhances the reactivity compared to that
of bare Fe<sup>+</sup>
DataSheet1_Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma.docx
Background: Diagnostic tools for hepatocellular carcinoma (HCC) are critical for patient treatment and prognosis. Thus, this study explored the diagnostic value of the exosomal microRNA panel for HCC.Methods: Expression profiles of microRNAs in exosomes and plasma of HCC and control groups were assessed using microRNA microarray analysis. Reverse transcription-quantitative PCR was applied to evaluate the expression of candidate microRNAs in blood samples from 50 HCC patients, 50 hepatic cirrhosis patients, and 50 healthy subjects. The area calculated the diagnostic accuracy of the microRNAs and microRNA panel under the receiver operating characteristic curve (AUC).Results: MicroRNA microarray analysis revealed that there were more differentially expressed microRNAs in the exosome HCC group than plasma HCC group. Among the 43 differentially expressed microRNAs contained in both exosomes and plasma, we finally decided to testify the expression and diagnostic significance of microRNA-26a, microRNA-29c, and microRNA-199a. The results indicated that expression of the microRNA-26a, microRNA-29c, and microRNA-199a in both exosomes and plasma was significantly lower in HCC patients compared with hepatic cirrhosis and healthy group. Interestingly, exosomal microRNAs were substantially more accurate in diagnosing HCC than microRNAs and alpha-fetoprotein in plasma. Moreover, the exosomal microRNA panel containing microRNA-26a, microRNA-29c, and microRNA-199a showed high accuracy in discriminating HCC from healthy (AUC = 0.994; sensitivity 100%; specificity 96%) and hepatic cirrhosis group (AUC = 0.965; sensitivity 92%; specificity 90%).Conclusion: This study revealed that the exosomal microRNA panel has high accuracy in diagnosing HCC and has important clinical significance.</p
Table1_Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma.xlsx
Background: Diagnostic tools for hepatocellular carcinoma (HCC) are critical for patient treatment and prognosis. Thus, this study explored the diagnostic value of the exosomal microRNA panel for HCC.Methods: Expression profiles of microRNAs in exosomes and plasma of HCC and control groups were assessed using microRNA microarray analysis. Reverse transcription-quantitative PCR was applied to evaluate the expression of candidate microRNAs in blood samples from 50 HCC patients, 50 hepatic cirrhosis patients, and 50 healthy subjects. The area calculated the diagnostic accuracy of the microRNAs and microRNA panel under the receiver operating characteristic curve (AUC).Results: MicroRNA microarray analysis revealed that there were more differentially expressed microRNAs in the exosome HCC group than plasma HCC group. Among the 43 differentially expressed microRNAs contained in both exosomes and plasma, we finally decided to testify the expression and diagnostic significance of microRNA-26a, microRNA-29c, and microRNA-199a. The results indicated that expression of the microRNA-26a, microRNA-29c, and microRNA-199a in both exosomes and plasma was significantly lower in HCC patients compared with hepatic cirrhosis and healthy group. Interestingly, exosomal microRNAs were substantially more accurate in diagnosing HCC than microRNAs and alpha-fetoprotein in plasma. Moreover, the exosomal microRNA panel containing microRNA-26a, microRNA-29c, and microRNA-199a showed high accuracy in discriminating HCC from healthy (AUC = 0.994; sensitivity 100%; specificity 96%) and hepatic cirrhosis group (AUC = 0.965; sensitivity 92%; specificity 90%).Conclusion: This study revealed that the exosomal microRNA panel has high accuracy in diagnosing HCC and has important clinical significance.</p
Table2_Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma.xlsx
Background: Diagnostic tools for hepatocellular carcinoma (HCC) are critical for patient treatment and prognosis. Thus, this study explored the diagnostic value of the exosomal microRNA panel for HCC.Methods: Expression profiles of microRNAs in exosomes and plasma of HCC and control groups were assessed using microRNA microarray analysis. Reverse transcription-quantitative PCR was applied to evaluate the expression of candidate microRNAs in blood samples from 50 HCC patients, 50 hepatic cirrhosis patients, and 50 healthy subjects. The area calculated the diagnostic accuracy of the microRNAs and microRNA panel under the receiver operating characteristic curve (AUC).Results: MicroRNA microarray analysis revealed that there were more differentially expressed microRNAs in the exosome HCC group than plasma HCC group. Among the 43 differentially expressed microRNAs contained in both exosomes and plasma, we finally decided to testify the expression and diagnostic significance of microRNA-26a, microRNA-29c, and microRNA-199a. The results indicated that expression of the microRNA-26a, microRNA-29c, and microRNA-199a in both exosomes and plasma was significantly lower in HCC patients compared with hepatic cirrhosis and healthy group. Interestingly, exosomal microRNAs were substantially more accurate in diagnosing HCC than microRNAs and alpha-fetoprotein in plasma. Moreover, the exosomal microRNA panel containing microRNA-26a, microRNA-29c, and microRNA-199a showed high accuracy in discriminating HCC from healthy (AUC = 0.994; sensitivity 100%; specificity 96%) and hepatic cirrhosis group (AUC = 0.965; sensitivity 92%; specificity 90%).Conclusion: This study revealed that the exosomal microRNA panel has high accuracy in diagnosing HCC and has important clinical significance.</p
Additional file 1: of A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies
Table S1. Detail information of primers. Table S2. Information of the most significantly up-regulated or down-regulated DEGs in HCC. Table S3. The expression values of 10 genes on all 5 HCC cases. (DOC 89 kb